Please try another search
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Name | Age | Since | Title |
---|---|---|---|
Ramon Martin Chavez Marquez | 57 | 2020 | Independent Chair of the Board |
Robert J. Lollini | 70 | 2014 | Member of Business Advisory Panel |
Terry-Ann Burrell | 47 | 2020 | Independent Director |
Joseph P. Miletich | 72 | 2021 | Chairman of Therapeutics Advisory Board |
Anne Carpenter | - | 2014 | Member of Scientific and Technical Advisory Board |
Kirk R. Thomas | - | 2014 | Member of Scientific & Technical Advisory Board |
H. Perry Fell | 67 | 2014 | Member of Business Advisory Panel |
Zavain Dar | 35 | 2016 | Independent Director |
Dean Y. Li | 61 | 2013 | Co-Founder & Independent Director |
Zachary S. Bogue | 49 | 2018 | Independent Director |
Robert M. Hershberg | 62 | 2020 | Independent Director |
Blake C. Borgeson | 42 | 2013 | Co-Founder & Director |
Christopher C. Gibson | 41 | 2013 | Co-Founder, CEO & Director |
Najat Khan | - | 2024 | Chief R&D Officer, Chief Commercial Officer and Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review